Study Summary
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD22 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
Want to learn more about this trial?
Request More InfoInterventions
CD19&CD22 bispecific CAR-T cellsDRUG
Each patient will receive CD19\&CD22 bispecific CAR-T cells by intravenous infusion on day 0
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei | China |